HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 59, Number 12, December 24, 2002 Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rutschmann, O. T. Articles by Matchar, D. B. Search for Related Content PubMed PubMed Citation Articles by Rutschmann, O. T. Articles by Matchar, D. B. Related Collections All Demyelinating disease (CNS) Multiple sclerosis

Immunization and MS

A summary of published evidence and recommendations

*See the Appendix on page 1843 for a list of Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines’ members.
From the Duke Center for Clinical Health Policy Research (Dr. Matchar), Duke University Medical Center, Durham, NC.

Address correspondence and reprint requests to Therapeutics and Technology Assessment, American Academy of Neurology, 1080 Montreal Avenue, St. Paul, MN 55116.

Objective: To review the risk of MS exacerbations after infectious episodes potentially preventable by vaccination, and the risks and benefits of immunizing patients with MS.

Methods: The authors searched MEDLINE (1966 to January 2001; U.S. National Library of Medicine, Bethesda, MD), HealthSTAR, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) database (Cinahl Information Systems, Glendale, CA) for English-language articles. Each study was summarized and rated for quality of evidence. Then feasible data were pooled and analyzed in meta-analysis.

Results: The risk of contracting common infectious diseases in patients with MS is not well established. There is strong evidence for an increased risk of MS exacerbations during weeks around an infectious episode. There is strong evidence against an increased risk of MS exacerbation after influenza immunization. There is no evidence that hepatitis B, varicella, tetanus, or Bacille Calmette–Guerin vaccines increase the risk of MS exacerbations. Insufficient evidence was found for other vaccines.

Conclusions: Evidence supports 1) strategies to minimize the risk of acquiring infectious diseases that may trigger exacerbations of MS; and 2) the safety of using influenza, hepatitis B, varicella, tetanus, and Bacille Calmette–Guerin (BCG) vaccines in patients with MS.

This article has been cited by other articles:

				Y. Mikaeloff, G. Caridade, S. Assi, M. Tardieu, S. Suissa, and on behalf of the KIDSEP study group of the French Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination Brain, April 1, 2007; 130(4): 1105 - 1110. [Abstract] [Full Text] [PDF]

				S. R. Schwid, M. D. Decker, M. Lopez-Bresnahan, and for the Rebif-Influenza Vaccine Study Investigator Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a Neurology, December 27, 2005; 65(12): 1964 - 1966. [Abstract] [Full Text] [PDF]

				S M Leary, B Porter, and A J Thompson Multiple sclerosis: diagnosis and the management of acute relapses Postgrad. Med. J., May 1, 2005; 81(955): 302 - 308. [Abstract] [Full Text] [PDF]

				R. T. Naismith and A. H. Cross Does the hepatitis B vaccine cause multiple sclerosis? Neurology, September 14, 2004; 63(5): 772 - 773. [Full Text] [PDF]